Longeveron (LGVN) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
3 Mar, 2026Executive summary
Special Meeting will be held virtually for shareholders to vote on two key proposals: a reverse stock split and potential adjournment to solicit more votes if needed.
The reverse stock split aims to increase the per-share price of Class A Common Stock to meet Nasdaq's minimum bid price requirement and enhance marketability.
The Board has discretion to set the split ratio between 1-for-5 and 1-for-20 and to determine the timing or abandonment of the split.
If approved, the split will reduce outstanding shares but not affect authorized share capital or materially change shareholder rights.
Risks include potential decreased liquidity, odd-lot holdings, and no guarantee of sustained price increase.
Voting matters and shareholder proposals
Shareholders will vote on: (1) amending the Certificate of Incorporation to effect a reverse stock split, and (2) adjourning the meeting if more time is needed to solicit votes.
The Board recommends voting FOR both proposals.
Stockholder proposals for the 2026 annual meeting must be submitted between February 15 and March 14, 2026.
Board of directors and corporate governance
The Board has full discretion to implement or abandon the reverse stock split up to December 31, 2026.
The Board may adjust the split ratio based on market conditions and company needs.
Latest events from Longeveron
- Positive clinical progress in stem cell therapies for rare and aging-related diseases.LGVN
Investor presentation18 Mar 2026 - $15M financing extends runway as pivotal HLHS trial nears, despite 50% revenue drop and higher losses.LGVN
Q4 202517 Mar 2026 - Directors elected, incentive plan amended, and auditors ratified; results to be filed.LGVN
AGM 20243 Feb 2026 - Revenue and cash up, net loss down, and FDA designations boost growth outlook.LGVN
Q2 20242 Feb 2026 - Revenue up 177%, pivotal trials advanced, and cash runway extends through Q4 2025.LGVN
Q3 202414 Jan 2026 - Lomecel-B advances toward pivotal approval in HLHS and Alzheimer's, targeting billion-dollar markets.LGVN
Emerging Growth Conference7711 Jan 2026 - Lomecel-B shows strong clinical progress in HLHS and Alzheimer's, targeting major unmet needs.LGVN
Biotech Showcase 202510 Jan 2026 - Pivotal trials and 237% revenue growth mark progress, with cash funding into Q4 2025.LGVN
Q4 202426 Dec 2025 - Pivotal HLHS trial nears completion, with BLA filing and accelerated Alzheimer's path planned.LGVN
37th Annual ROTH Conference26 Dec 2025